<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159195</url>
  </required_header>
  <id_info>
    <org_study_id>A5481090</org_study_id>
    <nct_id>NCT03159195</nct_id>
  </id_info>
  <brief_title>Ibrance Real World Insights [IRIS]</brief_title>
  <acronym>IRIS</acronym>
  <official_title>Treatment Patterns And Clinical Outcomes Among Patients Receiving Palbociclib Combinations For Hr+/her2- Advanced/Metastatic Breast Cancer In Real World Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe patient demographics, clinical characteristics, treatment patterns and clinical
      outcomes of adult female patients who have received palbociclib combination treatments in
      line with regional licensed indications in real world settings across multiple countries.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of patients progression free</measure>
    <time_frame>0 to 36 months</time_frame>
    <description>Proportion of patients who are progression free will be assessed at various timepoints between 0 and 36 months</description>
  </primary_outcome>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Malignant Neoplasm of Breast</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>CDK 4/6 inhibitor for advanced/ metastatic breast cancer</description>
    <other_name>Ibrance</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult female patients with HR+/HER2 advanced or metastatic breast cancer receiving
        palbociclib combination regimens as per the approved indication.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  â‰¥18 years old

          -  HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.

          -  Received palbociclib plus letrozole/aromatase inhibitor or palbociclib plus
             fulvestrant in line with the licenced indication(s)

          -  No prior or current enrolment in an interventional clinical trial for ABC/MBC

          -  Minimum of three months of follow up data since palbociclib with fulvestrant
             initiation, or minimum of six months of follow up data since palbociclib with
             letrozole/aromatase inhibitor initiation (core medical record review)

          -  Minimum of three months of follow up data since palbociclib initiation (interim
             medical record review)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female participants only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481090&amp;StudyName=Treatment+Patterns+And+Clinical+Outcomes+Among+Patients+Receiving+Palbociclib+Combinations+For+Hr%2B%2Fher2-+Advanced%2Fmetastatic+Breast+Cancer+In+Real+World+Settings</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>advanced breast cancer</keyword>
  <keyword>HR+/ HER2-</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

